Neutropenia - Drug Pipeline Analysis and Market Forecasts to 2016

Neutropenia Therapeutics Market Forecasts to Moderate Growth Until 2016

GlobalData estimated that the global neutropenia market was valued at $6.4 billion in
2009 and forecasts it to grow by 4% annually for the next seven years. The growth rate
of this market from 2001-2009 was 6%. This lower growth rate between the years 2009-
2016 as compared to the year 2001-2009 is because of the expiry of the patents for
Neulasta (pegfilgrastim) and Neupogen (filgrastim). Their patent will expire in the years
2015 and 2013 respectively. As a result, the market will shrink to some extent and then
grow to $8.6 billion in 2016. The market will decline in the years 2015-2016 from $8.7
billion to $8.6 billion because of the expiry of the patent of biggest selling drug Neulasta.
The growth in the market will be mainly due to the increase in the prevalence rate of
this disease, which is in turn is accelerated by the increasing prevalence rates of other
diseases such as cancer and cardiovascular disorders.
In addition to this, there is scarcity of pipeline molecules in neutropenia market.
Although there are a few blockbuster drugs in this pipeline, they will also be incapable
of getting the same growth rate as Neulasta and Neupogen have. There will also be the
introduction of biosimilars and generics in future that will add to this problem. Hence, in
the coming years the growth rate of this market will slump. Combining the effect of all
the three factors, the high prevalence rate, the introduction of biosimilars and the
scarce pipeline, it can be said that the market will have moderate growth rate in the
coming years.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Neutropenia-Drug-Pipeline-
Analysis-and-Market-Forecasts-to-
2016&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_He
althcare

Current Market is successful in Meeting Half of the Existing Market Need

GlobalData found that the existing drugs are moderately serving neutropenia market.
The current competition in this market is strong and due to the fact that the currently
marketed products are expensive, there remains a moderate level of unmet need in this
market. In 2009, the unmet need was approximately 50% of the current market
demand. Although the currently marketed and off-label products possess moderate
safety and moderate to high efficacy profiles, they lack novel mechanisms of action to
treat this disease. Most of the currently used products belong to the class of granulocyte
colony stimulating factors (G-CSFs). There are no other classes of products that are used
to treat this disease. This creates an unmet need of $3.2 billion in this market. This also
creates a market potential for new entrants that can take advantage of this scenario by
introducing products that are novel in their mechanism as well as cheaper than the
existing products. However, due to the tough competition posed by the currently
marketed players, it can be difficult for new entrants to survive. The competition will be
further intensified by the introduction of biosimilars, which are present in the pipeline.
In order to serve this market successfully, the companies need to treat this disease with
products that are more efficacious and safer than the existing products.

Competition in Neutropenia Market Will Remain Strong

According to GlobalData, Amgen is the market leader in the neutropenia market both in
terms of product dominance and market share. The other noticeable player in this
market is Bayer Inc. These two players cover almost the whole neutropenia market,
making it hard for other companies to enter. Approximately 50% of the market is
covered by Neulasta and 24% by Neupogen. Both these drugs are marketed by Amgen.
However, there are many more companies that might enter this market in the coming
years. Among them are Pfizer and Teva Pharmaceuticals, who may pose the most threat
to Amgen. The ease of making biosimilars to a drug makes the dynamics of this market
even more composite. Because of this ease, the market will witness introduction of
many biosimilars in coming years. With the expiry of the patents for Neulasta and
Neupogen, and with the introduction of biosimilars like Neugranin, the competition in
this market will be intensified.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Neutropenia-Drug-Pipeline-
Analysis-and-Market-Forecasts-to-
2016&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_He
althcare

GlobalData, the industry analysis specialist, has released a new report, “Neutropenia -
Drug Pipeline Analysis and Market Forecasts to 2016”. The report is an essential source
of information and analysis on the global neutropenia market. The report identifies the
key trends shaping and driving the global neutropenia market. The report also provides
insights into the prevalent competitive landscape and the emerging players expected to
cause significant shifts in the positioning of the existing market leaders. Most
importantly, the report provides valuable insight into the pipeline products within the
global neutropenia sector.

Visit our report store: http://www.globaldata.com/reportstore

Contact Information:
Rajesh Gunnam
rgunnam@globaldata.com
+914066166782